Outcome of Graves' disease after antithyroid drug treatment in Taiwan

Pei Wen Wang, Rue Tsuan Liu, Shih Chen Tung, Wen Yen Chien, Yung Chuan Lu, Chen Hsiong Chen, Ming Chun Kuo, Jing Rong Hsieh, Shan-Tair Wang

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

The outcome of Graves' disease after treatment with antithyroid drugs (ATDs) varies widely among countries, and large-scale studies in Asia are rare. We investigated the associations of various clinical and laboratory features with the outcome of ATD therapy for Graves' disease in Taiwan. A total of 210 patients (177 women, 33 men; mean ± SD age, 41.7 ± 15.1 yr) treated with ATD in Taiwan were included. ATD therapy started with methimazole 30 mg daily or propylthiouracil 300 mg daily and was continued until a euthyroid state was achieved. Afterwards, 154 patients received a maintenance dose of ATD alone, while 56 patients received a combination of an ATD and thyroxine (L-T4). Patients were considered to be in remission if they remained in a euthyroid state for more than 2 years after drug withdrawal. The mean follow-up periods were 45.0 ± 20.9 months for patients with remission and 30.4 ± 19.8 months for those with relapse. Relapse occurred in 126 (60%) patients during the follow-up period, within 3 months after drug withdrawal in 47 (37%), and within 6 months in 60 (46%). The relapse rate was 100% among patients with two or more previous relapses. Patients with a second occurrence had a higher relapse rate than those with a first occurrence (84% vs 43%). Past history of recurrence, goiter size, thyroid-stimulating hormone level and thyrotropin-binding inhibition immunoglobulin, activity at the end of ATD treatment were independently associated with relapse. Prolonged duration of treatment did not yield better results in patients with larger goiters or a history of recurrence, or both. Combination therapy with L-T4 yielded similar results to those achieved with ATD treatment alone. In conclusion, the relapse rate of Graves' disease after ATD treatment in Taiwanese patients was high, especially in those with a history of recurrence. The treatment duration and drug regimen did not affect the outcome.

Original languageEnglish
Pages (from-to)619-625
Number of pages7
JournalJournal of the Formosan Medical Association
Volume97
Issue number9
Publication statusPublished - 1998 Sep 1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Outcome of Graves' disease after antithyroid drug treatment in Taiwan'. Together they form a unique fingerprint.

Cite this